Fluconazole prophylaxis for critically ill patients at high risk for Candida infection [6]

Clinical Infectious Diseases

Volumn 41, Issue 11, 2005, Pages 1690-1691

  Garbino, J ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PLACEBO;

CANDIDIASIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CRITICAL ILLNESS; HIGH RISK PATIENT; HUMAN; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; MORTALITY; PERITONEUM; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDIASIS; CRITICAL ILLNESS; FLUCONAZOLE; FUNGEMIA; HUMANS;

EID: 28044444531     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498349     Document Type: Letter

References (4)

1. Wenzel RP, Gennings G. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005; 41(Suppl 6):S389-93.
2. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent Candida infections in critically ill surgical patients. Ann Surg 2001; 233:542-8.
3. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-17.
4. Garbino J, Rohner P, Romand J-A, Lew D, Pittet D. Candidemia at the ICU of a tertiary care hospital. Int J Infect Dis 2004; 8(S1):S133.